Literature DB >> 3190140

Development of anti-tumoral cell-mediated cytotoxicity during the course of Marek's disease in chickens.

P Queré1, G Dambrine.   

Abstract

Using a 3H-proline release assay, in vitro cell-mediated cytotoxic (CMC) response of spleen lymphocytes from B13B13 chickens infected with Marek's disease (MD) virus (MDV) was investigated during the course of infection. Syngeneic MD-specific anti-tumoral CMC and natural killer (NK) activity was compared from one to six weeks after infection. A parallel increase in the two types of CMC responses were demonstrated and effector cells with similar characteristics seemed to be involved. Anti-thymocyte serum (ATS) treatment and depletion of macrophage-like cells, using plastic adherence or carbonyl iron treatment, slightly reduced the CMC response against both types of target cells in MDV-infected chickens as well as in controls. Nevertheless, even after depletion treatment, a higher cytotoxic activity was maintained in MDV-inoculated chickens. The involvement of specific antibodies was excluded. It was concluded that the inoculation of the HPRS-16 strain of MDV in B13B13 chickens increased a splenic NK-like activity against lymphoblastoid cell lines, wether MDV-transformed or not. In chickens vaccinated with HVT (Herpes virus of turkey) at hatching, an increase of NK-activity was observed earlier, ie two weeks after MDV inoculation.

Entities:  

Mesh:

Year:  1988        PMID: 3190140

Source DB:  PubMed          Journal:  Ann Rech Vet        ISSN: 0003-4193


  4 in total

1.  Alterations of the MDV oncogenic regions in an MDV transformed lymphoblastoid cell line.

Authors:  E Le Rouzic; P Thoraval; M Afanassieff; Y Cherel; G Dambrine; B Perbal
Journal:  Mol Pathol       Date:  2002-08

Review 2.  Marek's disease in chickens: a review with focus on immunology.

Authors:  Nitish Boodhoo; Angila Gurung; Shayan Sharif; Shahriar Behboudi
Journal:  Vet Res       Date:  2016-11-28       Impact factor: 3.683

3.  The effects of in ovo administration of encapsulated Toll-like receptor 21 ligand as an adjuvant with Marek's disease vaccine.

Authors:  Jegarubee Bavananthasivam; Leah Read; Jake Astill; Alexander Yitbarek; Tamiru N Alkie; Mohamed Faizal Abdul-Careem; Sarah K Wootton; Shahriar Behboudi; Shayan Sharif
Journal:  Sci Rep       Date:  2018-11-06       Impact factor: 4.379

4.  Marek's Disease Virus Infection of Natural Killer Cells.

Authors:  Luca D Bertzbach; Daphne A van Haarlem; Sonja Härtle; Benedikt B Kaufer; Christine A Jansen
Journal:  Microorganisms       Date:  2019-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.